CD3xCD123 BsAB have clinical impact potential in MM as they may help treatment outcomes by blocking immune evasion via depletion of CD123+ MDSC and by reducing the drug-resistant tumor load via CTL-mediated MHC-independent destruction of MM stem cells. This evidence concerns the gene HLA-C and neoplasm.